tiprankstipranks
Trending News
More News >
Organogenesis Holdings Inc (ORGO)
NASDAQ:ORGO
Advertisement

Organogenesis Holdings (ORGO) AI Stock Analysis

Compare
465 Followers

Top Page

ORGO

Organogenesis Holdings

(NASDAQ:ORGO)

Rating:54Neutral
Price Target:
$5.00
▲(0.00% Upside)
Organogenesis Holdings faces significant challenges with declining revenue and profitability, impacting its financial performance and valuation. While technical analysis shows some potential for upward momentum, the negative P/E ratio and lack of dividend yield are concerning. The earnings call and recent corporate events highlight both strategic initiatives and ongoing financial difficulties.
Positive Factors
Market Positioning
ORGO is one of three companies listed on both the DFU and VLU covered lists, suggesting strong positioning in the market.
Product Pricing
The FY26 CMS proposal for skin substitutes is expected to benefit ORGO based on current product pricing.
Valuation
ORGO's valuation is seen as favorable risk/reward, suggesting potential for share price increase.
Negative Factors
LCD Implementation
ORGO's 1Q25 results were negatively impacted by continued LCD uncertainty regarding skin substitute grafts, where implementation has been delayed a third time to January 1, 2026.
Revenue
Revenue of $101.0M missed estimates due to LCD dynamics and changes to CMS' proposals impacting results.
Sales Guidance
ORGO lowered its FY25 guidance for total sales and adjusted EBITDA, indicating challenges in meeting previous expectations.

Organogenesis Holdings (ORGO) vs. SPDR S&P 500 ETF (SPY)

Organogenesis Holdings Business Overview & Revenue Model

Company DescriptionOrganogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.
How the Company Makes MoneyOrganogenesis generates revenue primarily through the sale of its advanced wound care and surgical biologics products. The company has established a diverse revenue model that includes direct sales to hospitals, outpatient clinics, and other healthcare providers. Key revenue streams come from product sales in the United States and internationally, supported by a strong sales force and distribution network. Additionally, Organogenesis benefits from collaborations and partnerships with healthcare institutions and payers, which enhance its market presence and facilitate access to its products. The company also invests in research and development to innovate and expand its product portfolio, contributing to long-term revenue growth through new offerings in the regenerative medicine space.

Organogenesis Holdings Earnings Call Summary

Earnings Call Date:Aug 07, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 05, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed outlook. While there are positive developments such as growth in the Surgical & Sports Medicine segment, proposed CMS payment reforms, and progress in the ReNu program, the company faced significant challenges with a decline in Advanced Wound Care revenue, overall revenue decrease, and reduced financial guidance.
Q2-2025 Updates
Positive Updates
Surgical & Sports Medicine Revenue Growth
Net product revenue from Surgical & Sports Medicine products for the second quarter was $8.1 million, up 16%.
Proposed CMS Payment Reform
CMS announced a proposed Medicare physician fee schedule expected to bring long-term stabilization to the skin substitute markets and encourage innovation. This is seen as a transformational opportunity for Organogenesis.
ReNu BLA Submission Progress
ReNu program is on track for submission by the end of this year, with all patients completing the second Phase III study. Top line data results expected in September 2025.
Expanded Manufacturing Capacity
Expansion of biomanufacturing capabilities at the new facility in Smithfield, Rhode Island, to support the introduction of new products like Dermagraft and TransCyte.
Negative Updates
Advanced Wound Care Revenue Decline
Advanced Wound Care net product revenue for the second quarter was $92.7 million, down 25% due to aggressive competitive pricing and delay in the effective date of the LCD.
Overall Revenue Decrease
Net product revenue for the second quarter was $100.8 million, down 23% year-over-year.
Reduced Financial Guidance
Updated 2025 revenue guidance assumes net revenue of between $480 million and $510 million, a reduction from previous expectations.
Decreased Gross Profit Margin
Gross profit for the second quarter was $73.1 million or 73% of net product revenue, compared to 78% last year, due to lower revenue over fixed costs and expiration of excess product.
Company Guidance
During the Second Quarter 2025 Earnings Conference Call, Organogenesis Holdings provided comprehensive guidance and insights into their performance and strategic developments. The company reported a net product revenue of $100.8 million for Q2, a 23% decrease year-over-year, influenced by a 25% decline in Advanced Wound Care products and a 16% increase in Surgical & Sports Medicine products. Gross profit was noted at $73.1 million, equating to 73% of net product revenue. The operating expenses were reduced by 21% to $113.6 million, resulting in an operating loss of $12.6 million. The GAAP net loss stood at $9.4 million, while the adjusted EBITDA loss was $3.6 million. Looking ahead, the company updated its 2025 revenue guidance to a range of $480 million to $510 million, with expected profitability influenced by a gross margin projection of 74% to 76%. Key strategic focuses included advocating for CMS policy reforms, expanding biomanufacturing capabilities, and advancing the ReNu program. The company also anticipated the reintroduction of Dermagraft by the second half of 2027 and emphasized the importance of new CMS payment proposals for the industry.

Organogenesis Holdings Financial Statement Overview

Summary
Organogenesis Holdings faces significant challenges with declining revenue, profitability, and cash flow generation in recent periods. The company's strong gross profit margin and low leverage are positive aspects, yet the negative net profit margins and declining equity raise concerns about its financial health. Management must address operational inefficiencies and enhance cash flow management to stabilize and improve the financial outlook.
Income Statement
45
Neutral
Organogenesis Holdings experienced a decline in revenue with a negative growth rate of around -4.82% from 2024 to TTM (Trailing-Twelve-Months), alongside a consistent downward trajectory since 2021. The company shows negative net profit margins and EBIT margins in the TTM, indicating operational challenges. However, gross profit margins remain strong at 74.89% in TTM, suggesting efficient cost management. Despite strong historical performance, recent declines highlight potential risks.
Balance Sheet
55
Neutral
The balance sheet reflects moderate stability with a debt-to-equity ratio of 0.18 in TTM, showcasing low leverage and prudent financial management. The equity ratio stands at 51.96%, indicating a healthy proportion of equity within the asset structure. However, declining stockholders' equity and rising liabilities over the periods pose risks to financial stability. The return on equity is negative in TTM, further pointing to profitability issues.
Cash Flow
40
Negative
The cash flow analysis reveals challenges with negative free cash flow in TTM, deteriorating from previous periods, indicating liquidity issues. The operating cash flow to net income ratio is 0.24, highlighting operational inefficiencies. While past periods showed positive free cash flow, recent figures suggest potential cash constraints, necessitating careful liquidity management.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue429.53M482.04M433.14M450.89M468.06M338.30M
Gross Profit313.68M366.30M326.66M345.87M353.86M250.98M
EBITDA-13.98M15.76M36.03M40.32M87.00M37.23M
Net Income-10.98M861.00K4.95M15.53M94.20M17.23M
Balance Sheet
Total Assets461.13M497.89M460.02M449.36M443.26M294.49M
Cash, Cash Equivalents and Short-Term Investments73.08M135.57M104.34M102.48M113.93M84.39M
Total Debt40.82M43.31M119.35M123.79M132.30M84.77M
Total Liabilities99.91M112.57M181.36M183.69M201.22M148.41M
Stockholders Equity361.22M385.32M278.66M265.67M242.03M141.81M
Cash Flow
Free Cash Flow-46.37M4.18M6.55M-9.04M30.76M-14.34M
Operating Cash Flow-33.18M14.21M30.92M24.86M61.98M6.80M
Investing Cash Flow-13.19M-10.03M-24.36M-33.90M-31.22M-24.83M
Financing Cash Flow29.63M27.64M-5.50M-2.20M-1.04M42.47M

Organogenesis Holdings Technical Analysis

Technical Analysis Sentiment
Positive
Last Price5.00
Price Trends
50DMA
4.54
Positive
100DMA
4.12
Positive
200DMA
4.01
Positive
Market Momentum
MACD
0.14
Negative
RSI
58.38
Neutral
STOCH
69.01
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORGO, the sentiment is Positive. The current price of 5 is above the 20-day moving average (MA) of 4.77, above the 50-day MA of 4.54, and above the 200-day MA of 4.01, indicating a bullish trend. The MACD of 0.14 indicates Negative momentum. The RSI at 58.38 is Neutral, neither overbought nor oversold. The STOCH value of 69.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ORGO.

Organogenesis Holdings Risk Analysis

Organogenesis Holdings disclosed 73 risk factors in its most recent earnings report. Organogenesis Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Organogenesis Holdings Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
$1.24B37.8716.16%22.61%-63.00%
70
Outperform
$1.46B-3.63%132.35%97.34%
66
Neutral
$1.58B32.1917.80%1.26%27.37%1898.99%
54
Neutral
$638.09M928.57-2.64%-4.21%7.78%
52
Neutral
$1.34B-18.99%47.69%69.57%
51
Neutral
$7.91B-0.36-41.71%2.23%23.45%-1.86%
44
Neutral
$485.79M-9999.00%17.15%-7.23%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ORGO
Organogenesis Holdings
5.00
2.53
102.43%
AVDL
Avadel Pharmaceuticals
15.76
1.27
8.76%
PAHC
Phibro Animal Health
39.45
20.34
106.44%
COLL
Collegium Pharmaceutical
39.23
2.04
5.49%
HROW
Harrow Health
36.20
-1.78
-4.69%
EOLS
Evolus
7.51
-7.20
-48.95%

Organogenesis Holdings Corporate Events

Private Placements and FinancingFinancial Disclosures
Organogenesis Amends Credit Agreement Amid Revenue Decline
Negative
Aug 7, 2025

On August 5, 2025, Organogenesis Holdings Inc. amended its Credit Agreement to adjust financial covenants and accommodate its fiscal needs. The company reported a decrease in net product revenue to $100.8 million for the second quarter of 2025, compared to $130.2 million in the same period of 2024, with a net loss of $9.4 million, indicating a challenging financial period.

Executive/Board ChangesShareholder Meetings
Organogenesis Holdings Approves Key Proposals at Annual Meeting
Neutral
Jun 24, 2025

On June 23, 2025, Organogenesis Holdings held its Annual Meeting of Stockholders where several key proposals were voted on and approved. The meeting included the re-election of Garrett Lustig to the board of directors and the election of other directors to serve until the next annual meeting. Additionally, stockholders approved the compensation for named executive officers and the issuance of over 20% of Class A common stock upon conversion of Series A Convertible Preferred Stock, which may be deemed a change of control under Nasdaq rules. The appointment of RSM US LLP as the independent registered public accounting firm for 2025 was also ratified.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 19, 2025